FDA Downplays Generic Drug Backlog But Plays Up Need For More Funding
Executive Summary
Concerns over FDA's backlog of unapproved abbreviated new drug applications are overblown, according to Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb